All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Baricitinib in SLE: Results from the phase III SLE-BRAVE trials
Outcomes in patients with systemic lupus erythematosus (SLE) remain poor, and trials for new drugs in SLE often have negative results. The SLE-BRAVE trials investigated the efficacy and...
Editorial theme | Treat-to-target in SLE
The treat-to-target (T2T) strategy is examined, along with a discussion of the advantages and disadvantages of its use when managing patients with SLE, in this first editorial theme article on treatment goals.
Are you a healthcare professional? What is your specialty?
Please select or type your specialty
By sharing this information, you can help ensure we continue to develop content that is of most relevance for our audience.
Thank you for submitting.